SPRO

Spero Therapeutics Inc

1.15

Oct 28 • 1:49 PM ET +0.01 (0.88%)

Healthcare Biotechnology USA Micro NASD

Oct 26, 8:07 AMSpero Therapeutics appoints Amy Rock Chief Regulatory and Quality Officer and Dae Gon Ha SVP Corporate Development

Peers: ARMP ANTX CRMD ACXP SCYX MCRB VIR IVVD ASMB BCRX

| Held by: VTI VXF IWC QQQS PRFZ BUSM DXUV

Scroll to Statements

Index	-
Market Cap	66.97M
Enterprise Value	18.24M
Income	7.38M
Sales	42.96M
Book/sh	0.76
Cash/sh	0.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	25
IPO	Nov 02, 2017

P/E	10.53
Forward P/E	-
PEG	-
P/S	1.56
P/B	1.51
P/C	1.32
P/FCF	3.42
EV/EBITDA	7.07
EV/Sales	0.42
Quick Ratio	6.12
Current Ratio	6.12
Debt/Eq	0.05
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	0.11
EPS next Y	-0.93
EPS next Q	-0.47
EPS this Y	-746.67%
EPS next Y	4.12%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	7.06% 197.00%
EPS Y/Y TTM	114.38%
Sales Y/Y TTM	26.04%
EPS Q/Q	-443.89%
Sales Q/Q	-100.00%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	- -

Insider Own	26.19%
Insider Trans	-0.17%
Inst Own	15.56%
Inst Trans	1.65%
ROA	12.85%
ROE	19.17%
ROIC	16.69%
Gross Margin	-
Oper. Margin	6.00%
Profit Margin	17.18%
SMA20	-0.43%
SMA50	-2.52%
SMA200	-42.41%
Trades

Shs Outstand	58.15M
Shs Float	42.98M
Short Float	1.96%
Short Ratio	1.31
Short Interest	0.84M
52W High	3.08 -62.66%
52W Low	1.04 10.58%
Volatility	5.06% 5.80%
ATR (14)	0.07
RSI (14)	48.72
Beta	1.57
Rel Volume	0.58
Avg Volume	639.79K
Volume	254,161

Perf Week	-1.71%
Perf Month	-4.17%
Perf Quarter	-4.17%
Perf Half Y	-54.55%
Perf YTD	-50.64%
Perf Year	-51.68%
Perf 3Y	12.75%
Perf 5Y	-93.44%
Perf 10Y	-
Recom	1.00
Target Price	6.00
Prev Close	1.14
Price	1.15
Change %	0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Cantor Fitzgerald	Overweight	$6
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line	$5
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform	$2 → $8
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy	$33 → $40
Dec-16-20	Initiated	Berenberg	Buy	$47
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy	$28 → $35
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight	$27
Nov-27-17	Initiated	Stifel	Buy	$26
Nov-27-17	Initiated	Oppenheimer	Outperform	$30
Nov-27-17	Initiated	BofA/Merrill	Neutral	$16

Show Previous Ratings

Oct-26-26 08:00AM	Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline (GlobeNewswire)
Oct-15-26 04:05PM	Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference (GlobeNewswire)
Oct-02-26 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
Sep-03-26 04:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-26 04:01PM	Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
01:01AM	Loading…
Aug-13-26 01:01AM	Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... (GuruFocus.com)
Aug-12-26 04:01PM	Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update (GlobeNewswire)
Aug-05-26 04:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-04-26 04:01PM	Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 (GlobeNewswire) +6.96%
Jul-27-26 08:00AM	Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Jul-15-26 06:01AM	Innovent licenses IBI355 rights to Spero for up to $1.1bn (Pharmaceutical Technology)
05:18AM	J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals (BioPharma Dive)
Jul-14-26 06:46AM	Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) (InvestorsHub) -22.02%
06:02AM	Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties (GlobeNewswire)
06:00AM	Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody (GlobeNewswire)
09:52AM	Loading…
Jun-18-26 09:52AM	Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO) (InvestorsHub) +8.06%
Jun-17-26 04:21PM	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) (Business Wire) -23.83%
May-13-26 04:05PM	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update (GlobeNewswire) +13.11%
May-05-26 04:05PM	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 (GlobeNewswire)
Apr-22-26 06:03PM	Inventiva Builds Up Leadership Team Ahead of Potential Commercialization (Exec Edge)
Mar-26-26 04:05PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update (GlobeNewswire)
Mar-18-26 04:05PM	Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 (GlobeNewswire)
Feb-04-26 08:31AM	GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook (Zacks) +7.01%
Dec-19-25 08:00AM	Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis (GlobeNewswire)
Nov-28-25 08:00AM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-25 04:05PM	Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire) -8.27%
Nov-04-25 04:05PM	Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 (GlobeNewswire)
Oct-21-25 02:00AM	PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) (GlobeNewswire)
Oct-14-25 08:00AM	Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek (GlobeNewswire)
Oct-10-25 10:00AM	Best Momentum Stock to Buy for October 10th (Zacks)
11:23AM	Loading…
Oct-08-25 11:23AM	Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease (Zacks) +5.56%
Aug-19-25 09:35AM	Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround (Zacks)
Aug-13-25 03:11AM	Spero Therapeutics Inc (SPRO) Q2 2025 Earnings Call Highlights: Tepipenem HBR Trial Success and ... (GuruFocus.com) -18.01%
Aug-12-25 04:01PM	Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire) +7.27%
Aug-05-25 04:05PM	Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 (GlobeNewswire) -6.19% +6.60%
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
May-29-25 01:15PM	Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone (Insider Monkey) -9.36%
11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
May-28-25 07:00AM	GSK-licensed antibiotic meets goal in late-stage study (BioPharma Dive) +244.57%
07:00AM	Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee (GlobeNewswire)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +13.11% -5.78%
04:01PM	Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire)
May-12-25 09:53AM	Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-09-25 08:20AM	UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +7.83%
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-07-25 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-25 08:00AM	Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 (GlobeNewswire) -5.72%
Apr-28-25 04:01PM	Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer (GlobeNewswire) -5.49%
Mar-28-25 07:10AM	Q4 2024 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -10.88%
03:03AM	Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
Mar-27-25 08:31PM	Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript (Seeking Alpha)
05:20PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Mar-18-25 08:00AM	Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 (GlobeNewswire)
Feb-25-25 10:15AM	UPDATE Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
07:00AM	Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-15-25 12:00PM	Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know (Zacks) -7.90%
Jan-10-25 07:00AM	Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes (GlobeNewswire)
Dec-16-24 06:34PM	Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-24 12:09PM	TenNors Phase III antibiotic trial meets all primary endpoints (Clinical Trials Arena)
Nov-14-24 05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.60%
04:05PM	Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Nov-13-24 07:29AM	What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings (GuruFocus.com)
Nov-07-24 04:05PM	Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 (GlobeNewswire)
Oct-30-24 08:45AM	Speros stock slides after antibiotic flops in Phase II trial (Pharmaceutical Technology)
Oct-29-24 04:05PM	Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update (GlobeNewswire)
Oct-16-24 04:05PM	Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 (GlobeNewswire)
Oct-02-24 04:30PM	Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy (GlobeNewswire)
Sep-04-24 04:05PM	Spero Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-06-24 07:51AM	Q2 2024 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.22%
Aug-05-24 08:59PM	SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Jul-29-24 04:05PM	Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 (GlobeNewswire)
Jul-08-24 03:07PM	3 Micro-Cap Moonshots for Fearless Investors (InvestorPlace)
Jul-03-24 01:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 04:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-24 04:05PM	Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference (GlobeNewswire)
May-15-24 08:55PM	SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:00AM	Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 (GlobeNewswire)
May-01-24 04:07PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.80%
Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Mar-15-24 12:51PM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:33AM	Q4 2023 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:10PM	Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update (GlobeNewswire)
Mar-06-24 08:05AM	Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-28-24 08:05AM	Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections (GlobeNewswire)
Feb-26-24 08:05AM	Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference (GlobeNewswire)
Feb-05-24 11:27PM	Spero Therapeutics Inc CEO Sath Shukla Sells 75,994 Shares (GuruFocus.com)
Jan-31-24 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-24 04:07AM	15 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Jan-25-24 04:40AM	11 Hyper-Growth Stocks Billionaires Are Loading Up On (Insider Monkey)
Jan-05-24 08:05AM	Spero Therapeutics Provides Corporate Update and 2024 Outlook (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rajavelu Esther	See Remarks	May 04 '26	Sale	2.51	25,240	63,352	986,851	May 06 09:53 PM
Rajavelu Esther	See Remarks	Feb 06 '26	Sale	2.36	87,917	207,484	1,012,091	Feb 09 09:31 PM
Keutzer Timothy	Chief Operating Officer	Feb 06 '26	Sale	2.36	18,652	44,019	742,506	Feb 09 09:09 PM
Keutzer Timothy	Chief Operating Officer	Feb 03 '26	Sale	2.14	24,224	51,839	764,629	Feb 05 06:30 AM
Keutzer Timothy	Chief Operating Officer	Feb 02 '26	Sale	2.20	18,891	41,560	788,853	Feb 05 06:30 AM
Keutzer Timothy	Chief Operating Officer	Feb 04 '26	Sale	2.24	3,471	7,775	761,158	Feb 05 06:30 AM
Rajavelu Esther	See Remarks	Feb 02 '26	Sale	2.20	18,442	40,572	1,100,008	Feb 04 09:44 PM
Rajavelu Esther	See Remarks	Nov 07 '25	Sale	2.37	40,270	95,440	869,450	Nov 12 08:44 PM

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

CEOMs. Esther P. Rajavelu

Chief Operating OfficerMr. Timothy Keutzer

Senior Vice President of Finance & Business OperationsMr. John Raymond

Ph.D.Dr. Debra Jeske Zack M.D.

Senior VP & ControllerMs. Sheila Finan

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRO

Spero Therapeutics Inc

Upgrade your Finviz experience